Pharma’s Upcoming Messaging Battles In US Pricing Debate Foreshadowed In CBO Report
Our infographic offers the top takeaways from Congressional Budget Office report that says lower drug prices would decrease industry’s spend on research and development, while rejecting claim that costs of R&D set or impact a particular medicines price.
You may also be interested in...
Trade group’s new agenda offers few original solutions to tackle US drug costs, relying on old standbys and reminders of what medical innovation might be lost if industry is financially targeted by policy makers with a strong nod to drug manufacturers role the current pandemic.
A lot of new drugs aren’t really all that innovative, which complicates the view that lower profitability will mean less biopharma innovation.
Or can industry thread the donut hole and prevent government price negotiations from becoming a part of the legislative tsunami?